A vaccine company founded by the Medicxi investment group has raised $100 million in a Series B financing round to develop multivalent respiratory virus vaccines. The company, Vicebio Ltd, recently started a Phase 1 trial with its lead product, VXB-241, a bivalent vaccine targeting both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). The viruses affect elderly patients and those with weakened immune systems.
